Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract

Respiration

Volumn 84, Issue 4, 2012, Pages 319-326

  Chiang, Huai Chih ^a,e   Wang, Chien Kai ^b,c,d   Tsou, Tsui Chun ^a,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b Division of Hematology and Oncology   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

CYP2A13; CYP2A6; Immunohistochemistry; Metabolic activation; Respiratory tract

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; ENZYME ANTIBODY; EPITOPE; UNCLASSIFIED DRUG;

ARTICLE; BRONCHIOLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CROSS REACTION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; METABOLIC ACTIVATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYSTEM; SEQUENCE ANALYSIS;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BRONCHI; BRONCHIOLES; CARCINOGENS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PULMONARY ALVEOLI; RESPIRATORY SYSTEM; TISSUE DISTRIBUTION; TRACHEA;

EID: 84867054081     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000339591     Document Type: Article

References (37)

1. Adcock IM, Caramori G, Barnes PJ: Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011; 81: 265-284.
2. Rooney C, Sethi T: The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer. Respiration 2011; 81: 89-104.
3. Miyamoto M, Umetsu Y, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Nemoto N, Sato K, Ariyoshi N, Kamataki T: CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 1999; 261: 658-660.
4. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, Lin D: Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003; 63: 8057-8061.
5. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T: Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male japanese smokers. Carcinogenesis 2004; 25: 2451-2458.
6. Rossini A, de Almeida Simao T, Albano RM, Pinto LF: CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 2008; 9: 1737-1752.
7. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X: Human cytochrome P450 CYP2A13:Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. Cancer Res 2000; 60: 5074-5079.
8. He XY, Shen J, Ding X, Lu AY, Hong JY: Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab Dispos 2004; 32: 1516-1521.
9. Wong HL, Murphy SE, Hecht SS: Cytochrome P450 2A-catalyzed metabolic acti vation of structurally similar carcinogenic nitrosamines: Nnitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. Chem Res Toxicol 2005; 18: 61-69.
10. Aoyama T, Yamano S, Guzelian PS, Gelboin HV, Gonzalez FJ: Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci USA 1990; 87: 4790-4793.
11. He XY, Tang L, Wang SL, Cai QS, Wang JS, Hong JY: Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer 2006; 118: 2665-2671.
12. Duescher RJ, Elfarra AA: Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. Arch Biochem Biophys 1994; 311: 342-349.
13. Tiano HF, Wang RL, Hosokawa M, Crespi C, Tindall KR, Langenbach R: Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 1994; 15: 2859-2866.
14. Fujita K, Kamataki T: Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ Mol Mutagen 2001; 38: 339-346.
15. Chiang HC, Wang CY, Lee HL, Tsou TC: Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation-a mammalian cell-based mutagenesis approach. Toxicol Appl Pharmacol 2011; 253: 145-152.
16. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR, et al: A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57: 651-660.
17. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, Yokoi T: CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 2006; 119: 2520-2526.
18. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, Anttila S, Fernandez-Salguero P, Gonzalez F, Raunio H: Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999; 57: 1407-1413.
19. Zhu LR, Thomas PE, Lu G, Reuhl KR, Yang GY, Wang LD, Wang SL, Yang CS, He XY, Hong JY: CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 2006; 34: 1672-1676.
20. Fukami T, Nakajima M, Matsumoto I, Zen Y, Oda M, Yokoi T: Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci 2010; 101: 1024-1028.
21. Kyte J, Doolittle RF: A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157: 105-132.
22. Kolaskar AS, Tongaonkar PC: A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990; 276: 172-174.
23. Tsou TC, Tsai FY, Wu MC, Chang LW: The protective role of NF-B and AP-1 in arsenite-induced apoptosis in aortic endothelial cells. Toxicol Appl Pharmacol 2003; 191: 177-187.
24. Tsou TC, Yeh SC, Tsai FY, Chang LW: The protective role of intracellular GSH status in the arsenite-induced vascular endothelial dysfunction. Chem Res Toxicol 2004; 17: 208-217.
25. Ding X, Kaminsky LS: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43: 149-173.
26. Jalas JR, Hecht SS, Murphy SE: Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005; 18: 95-110.
27. Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, Alaoui-Jamali MA: Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 1996; 24: 458-467.
28. Raunio H, Juvonen R, Pasanen M, Pelkonen O, Paakko P, Soini Y: Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 1998; 27: 427-432.
29. Leclerc J, Tournel G, Courcot-Ngoubo Ngangue E, Pottier N, Lafitte JJ, Jaillard S, Mensier E, Lhermitte M, Broly F, Lo-Guidice JM: Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: differential expression in non-small cell lung cancers. Biochimie 2010; 92: 292-306.
30. Zhang X, D'Agostino J, Wu H, Zhang QY, von Weymarn L, Murphy SE, Ding X: CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone. J Pharmacol Exp Ther 2007; 323: 570-578.
31. Smith GB, Bend JR, Bedard LL, Reid KR, Petsikas D, Massey TE: Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab Dispos 2003; 31: 1134-1141.
32. Smith GB, Castonguay A, Donnelly PJ, Reid KR, Petsikas D, Massey TE: Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone (NNK) in freshly isolated human lung cells. Carcinogenesis 1999; 20: 1809-1818.
33. Brown PJ, Bedard LL, Reid KR, Petsikas D, Massey TE: Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes. Drug Metab Dispos 2007; 35: 2086-2094.
34. Ding S, Lake BG, Friedberg T, Wolf CR: Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 1995; 306(pt 1):161-166.
35. Brooks DR, Austin JH, Heelan RT, Ginsberg MS, Shin V, Olson SH, Muscat JE, Stellman SD: Influence of type of cigarette on peripheral versus central lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 576-581.
36. Hong JY, Wang YY, Bondoc FY, Lee M, Yang CS, Hu WY, Pan J: Metabolism of methyl tert-butyl ether and other gasoline ethers by human liver microsomes and heterologously expressed human cytochromes P450: identification of CYP2A6 as a major catalyst. Toxicol Appl Pharmacol 1999; 160: 43-48.
37. Fukami T, Katoh M, Yamazaki H, Yokoi T, Nakajima M: Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Chem Res Toxicol 2008; 21: 720-725.